Biofil Chemicals and Pharmaceuticals Limited (BIOFILCHEM.BO)
INR 61.06
(-0.33%)
INR 61.06
(-0.33%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 9.06 Million INR | -43.51% |
| 2022 | 7.38 Million INR | -18.42% |
| 2021 | 9.05 Million INR | -23.75% |
| 2020 | 11.87 Million INR | -16.11% |
| 2019 | 14.15 Million INR | 114.88% |
| 2018 | 6.58 Million INR | 2.91% |
| 2017 | 6.39 Million INR | -72.61% |
| 2016 | 23.36 Million INR | 285.69% |
| 2015 | 6.05 Million INR | -35.81% |
| 2014 | 9.43 Million INR | 17.75% |
| 2013 | 8.01 Million INR | -6.93% |
| 2012 | 8.6 Million INR | 252.94% |
| 2011 | 2.43 Million INR | -75.62% |
| 2010 | 10 Million INR | 82.56% |
| 2009 | 5.48 Million INR | 205.97% |
| 2008 | -5.17 Million INR | -35.04% |
| 2007 | -3.83 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 2.09 Million INR | 290.27% |
| 2023 Q1 | 3.1 Million INR | 3.47% |
| 2023 Q3 | 856 Thousand INR | -34.71% |
| 2023 Q4 | -1.1 Million INR | -228.5% |
| 2023 FY | 4.17 Million INR | -43.51% |
| 2023 Q2 | 1.31 Million INR | -57.76% |
| 2022 Q2 | 479 Thousand INR | -82.26% |
| 2022 FY | 7.38 Million INR | -18.42% |
| 2022 Q4 | 3 Million INR | 148.55% |
| 2022 Q3 | 1.2 Million INR | 151.98% |
| 2022 Q1 | 2.7 Million INR | 1058.8% |
| 2021 Q1 | 2.3 Million INR | 26.37% |
| 2021 FY | 9.05 Million INR | -23.75% |
| 2021 Q3 | 3.82 Million INR | 42.2% |
| 2021 Q2 | 2.69 Million INR | 17.04% |
| 2021 Q4 | 233 Thousand INR | -93.91% |
| 2020 Q4 | 1.82 Million INR | -65.27% |
| 2020 Q2 | 9.47 Million INR | 292.82% |
| 2020 Q3 | 5.24 Million INR | -44.66% |
| 2020 FY | 11.87 Million INR | -16.11% |
| 2020 Q1 | 2.41 Million INR | -43.75% |
| 2019 Q4 | 4.28 Million INR | 32.32% |
| 2019 FY | 14.15 Million INR | 114.88% |
| 2019 Q1 | 748 Thousand INR | -58.42% |
| 2019 Q2 | 8.24 Million INR | 1001.6% |
| 2019 Q3 | 3.23 Million INR | -60.69% |
| 2018 Q4 | 1.79 Million INR | -45.8% |
| 2018 FY | 6.58 Million INR | 2.91% |
| 2018 Q1 | 1.02 Million INR | -55.68% |
| 2018 Q2 | 1.44 Million INR | 40.21% |
| 2018 Q3 | 3.31 Million INR | 130.49% |
| 2017 Q3 | 2.61 Million INR | 135.95% |
| 2017 Q1 | 1.35 Million INR | -91.4% |
| 2017 Q2 | 1.1 Million INR | -18.06% |
| 2017 FY | 6.39 Million INR | -72.61% |
| 2017 Q4 | 2.31 Million INR | -11.29% |
| 2016 Q3 | 5.29 Million INR | 70.08% |
| 2016 Q2 | 3.11 Million INR | 395.86% |
| 2016 Q1 | 628 Thousand INR | -91.71% |
| 2016 Q4 | 15.7 Million INR | 196.48% |
| 2016 FY | 23.36 Million INR | 285.69% |
| 2015 FY | 6.05 Million INR | -35.81% |
| 2015 Q3 | 1.58 Million INR | 26.21% |
| 2015 Q1 | 903 Thousand INR | -81.72% |
| 2015 Q2 | 1.25 Million INR | 39.42% |
| 2015 Q4 | 7.57 Million INR | 376.78% |
| 2014 Q2 | 1.87 Million INR | 113.31% |
| 2014 Q4 | 4.93 Million INR | 332.15% |
| 2014 FY | 9.43 Million INR | 17.75% |
| 2014 Q3 | 1.14 Million INR | -39.04% |
| 2014 Q1 | 879 Thousand INR | -56.71% |
| 2013 Q3 | 4.46 Million INR | 578.57% |
| 2013 Q1 | 832 Thousand INR | -87.58% |
| 2013 FY | 8.01 Million INR | -6.93% |
| 2013 Q2 | 658 Thousand INR | -20.91% |
| 2013 Q4 | 2.03 Million INR | -54.52% |
| 2012 Q1 | 742 Thousand INR | 37.66% |
| 2012 Q4 | 6.69 Million INR | 1026.01% |
| 2012 FY | 8.6 Million INR | 252.94% |
| 2012 Q3 | 595 Thousand INR | 4.02% |
| 2012 Q2 | 572 Thousand INR | -22.91% |
| 2011 FY | 2.43 Million INR | -75.62% |
| 2011 Q4 | 538.99 Thousand INR | 17.43% |
| 2011 Q3 | 459 Thousand INR | 0.0% |
| 2010 FY | 10 Million INR | 82.56% |
| 2009 FY | 5.48 Million INR | 205.97% |
| 2008 FY | -5.17 Million INR | -35.04% |
| 2008 Q4 | -3.3 Million INR | 0.0% |
| 2007 FY | -3.83 Million INR | 0.0% |
| 2007 Q4 | -3.66 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Ajanta Pharma Limited | 19.67 Billion INR | 99.954% |
| Amrutanjan Health Care Limited | 457.54 Million INR | 98.018% |
| Sigachi Industries Limited | 1.47 Billion INR | 99.385% |
| Bal Pharma Limited | 233.9 Million INR | 96.123% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | 99.795% |
| Medico Remedies Limited | 100.3 Million INR | 90.958% |
| Lasa Supergenerics Limited | -458 Million INR | 101.98% |
| Venus Remedies Limited | 534.65 Million INR | 98.304% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 100.22% |
| Alpa Laboratories Limited | 184.49 Million INR | 95.085% |
| Nectar Lifesciences Limited | 923.8 Million INR | 99.018% |
| Shilpa Medicare Limited | 1.36 Billion INR | 99.336% |
| Aarti Drugs Limited | 7.14 Billion INR | 99.873% |
| Lupin Limited | 28.04 Billion INR | 99.968% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 99.979% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 99.979% |
| Windlas Biotech Limited | 1.29 Billion INR | 99.302% |
| Suven Life Sciences Limited | -1.22 Billion INR | 100.74% |
| Eris Lifesciences Limited | 5.18 Billion INR | 99.825% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 99.937% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 100.235% |
| Ipca Laboratories Limited | 7.98 Billion INR | 99.886% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | 99.263% |
| Achyut Healthcare Limited | 4.43 Million INR | -104.342% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 99.991% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| RPG Life Sciences Limited | 2.29 Billion INR | 99.604% |
| Mankind Pharma Limited | 21.51 Billion INR | 99.958% |
| Laurus Labs Limited | 3.94 Billion INR | 99.77% |
| Piramal Pharma Limited | 4.55 Billion INR | 99.801% |
| Syncom Formulations (India) Limited | 249.25 Million INR | 96.362% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 99.964% |
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 99.843% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 99.861% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | 98.552% |
| Wanbury Limited | 569.71 Million INR | 98.408% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 99.803% |
| Wockhardt Limited | -670 Million INR | 101.354% |
| Themis Medicare Limited | 392.58 Million INR | 97.69% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | 98.215% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 99.825% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 99.899% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 99.987% |
| Divi's Laboratories Limited | 33.08 Billion INR | 99.973% |
| NATCO Pharma Limited | 25.96 Billion INR | 99.965% |
| Gufic Biosciences Limited | 1.32 Billion INR | 99.318% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | 99.432% |
| Ind-Swift Limited | 1.22 Billion INR | 99.26% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 99.674% |
| FDC Limited | 2.98 Billion INR | 99.696% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 105.968% |
| Granules India Limited | 6.81 Billion INR | 99.867% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Alkem Laboratories Limited | 19.46 Billion INR | 99.953% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | 99.472% |
| Brooks Laboratories Limited | 14.44 Million INR | 37.197% |
| Megasoft Limited | -121.1 Million INR | 107.488% |
| ZIM Laboratories Limited | 253.82 Million INR | 96.427% |
| Strides Pharma Science Limited | 5.22 Billion INR | 99.826% |
| Neuland Laboratories Limited | 5.31 Billion INR | 99.829% |
| Morepen Laboratories Limited | 4.17 Billion INR | 99.783% |
| Hikal Limited | 32.11 Million INR | 71.757% |
| Indoco Remedies Limited | 1.29 Billion INR | 99.298% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 99.71% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | 95.641% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | 66.972% |
| Hester Biosciences Limited | 364.81 Million INR | 97.514% |